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Abstract
Background: Respiratory syncytial virus (RSV) infection is the second most important cause of death in the first year of life,
and early RSV infections are associated with the development of asthma. Breastfeeding and serum IgG have been shown to
protect against RSV infection. Yet, many infants depend on bovine milk-based nutrition, which at present lacks intact
immunoglobulins.
Objective: To investigate whether IgG purified from bovine milk (bIgG) can modulate immune responses against human
RSV.
Methods: ELISAs were performed to analyse binding of bIgG to human respiratory pathogens. bIgG or hRSV was coated to
plates to assess dose-dependent binding of bIgG to human Fcc receptors (FccR) or bIgG-mediated binding of myeloid cells
to hRSV respectively. S. Epidermidis and RSV were used to test bIgG-mediated binding and internalisation of pathogens by
myeloid cells. Finally, the ability of bIgG to neutralise infection of HEp2 cells by hRSV was evaluated.
Results: bIgG recognised human RSV, influenza haemagglutinin and Haemophilus influenza. bIgG bound to FccRII on
neutrophils, monocytes and macrophages, but not to FccRI and FccRIII, and could bind simultaneously to hRSV and human
FccRII on neutrophils. In addition, human neutrophils and dendritic cells internalised pathogens that were opsonised with
bIgG. Finally, bIgG could prevent infection of HEp2 cells by hRSV.
Conclusions: The data presented here show that bIgG binds to hRSV and other human respiratory pathogens and induces
effector functions through binding to human FccRII on phagocytes. Thus bovine IgG may contribute to immune protection
against RSV.
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Introduction
Respiratory syncytial virus (RSV) infection is a major cause of
death in the first year of life, with especially high mortality rates in
African and Asian countries [1,2,3]. Upper respiratory tract
infections (URTI) with RSV generally cause relatively mild disease
that does not require treatment. These infections can progress,
however, into lower respiratory tract infections (LRTI) and cause
severe disease, especially in pre-mature infants. RSV can also
cause recurrent infection of the upper respiratory tract.
An important complication of upper respiratory infections is
middle ear inflammation and-related deafness [4,5], and RSV
infections are associated with the development of asthma at a later
age [6,7,8].
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Other common causes for respiratory tract infections are
Haemophilus influenzae type b (Hib), parainfluenza virus,
rhinovirus and influenza virus [9,10,11].
Protective immunity against respiratory pathogens like influenza
and RSV is mediated by IgG and IgA [12,13,14,15,16]. RSV-
specific serum IgG levels in neonates are inversely associated with
increased prevalence of RSV infections [17,18], and breastfeeding
reduces the incidence and severity of RSV infection [19,20]. In
addition, the levels of anti-influenza IgA in breast milk correlates
with decreased frequency of respiratory illness with fever [16].
These findings indicate that pathogen-specific antibodies are
crucial for protection against respiratory infections, and that orally
ingested immunoglobulins (like breastmilk-derived IgA) may
contribute to immunity to airway infections.
Human and bovine milk contain high levels of immunoglob-
ulins, which are important for protecting the infant from infections
with bacteria and viruses [21,22]. Cross-species activity between
human and bovine immune-related milk proteins has been
reported before [23,24], and cow’s milk contains bovine IgG
(bIgG) that binds to gastrointestinal pathogens that also infect
humans, such as Shigella flexneri, Escherichia coli, Clostridium
difficile, Streptococcus mutants, Cryptosporidium parvum, Helico-
bacter pylori, and rotavirus [25].
At present there is, however, no information on binding of
bovine IgG to human respiratory viruses.
Most infant nutrition is bovine milk-based, but lacks intact bIgG
as a result of heat treatment during processing. To investigate if
bIgG would be a useful ingredient in these formulas, the aim of the
present study was to investigate the specificity and functional
relevance of bIgG against RSV and other human respiratory
pathogens, the ability of bIgG to bind to human Fcc receptors,
and the induction of effector functions in human myeloid cells.
Materials and Methods
Bovine milk samples and preparation of bIgG
bIgG was purified from commercially available bovine colos-
trum (Colostrum 35% IgG, Reflex Nutrition, Bristol, UK) using an
AFFI-TTM column (Kem-en-Tec) followed by a protein G column
(5 ml; Amersham). bIgG was eluted with 0.1 M glycine-HCl
pH 2.7 elution buffer and neutralised with 1 M Tris-HCl pH 9.0,
followed by dialysation against PBS and sterilisation (0.2 mm
filter). Fresh milk and colostrum samples were supplied by
FrieslandCampina (the Netherlands).
Detection of pathogen-specific IgG
Maxisorb ELISA-plates (Nunc) were coated with 0.5–2 mg/ml
pathogen antigens, derived from human vaccines (Influvac 2012/
2013 (0.5 mg/ml), Abbott Biologicals), Act-HIB (Sanofi pasteur
MSD (0.5 mg/ml)), DTP (1/200, Nederland vaccine instituut), or
25 ml inactivated RSV A2 or rhinovirus (kindly provided by Prof.
S Johnston, Imperial College London, UK). Plates were blocked
with 0.5% gelatine/PBS, washed (0.05% tween-20/PBS), and
samples were added and titrated. Plates were washed four times
and 1/2000 HRP-conjugated sheep anti bovine IgG1 (Abd
Serotec, Kidlington, UK) or 1/6000 anti-human IgG (Jackson
ImmunoResearch, West Grove, PA, USA) were used as detector
antibody. Plates were washed extensively and developed with
TMB and read at 450 nm. For inhibition ELISAs purified IgG
from human plasma (Intravenous Immunoglobulin, pooled from
.1000 donors, or IVIg) (Sanquin blood supply, The Netherlands)
or bIgG equivalent to 167 mg/ml was pre-incubated at room
temperature with twice the amount used for coating of hRSV or
vaccine. Binding to F protein of bRSV was analysed by a
commercial ELISA, according to the manufacturer’s descriptions
(Bio-X Diagnostics, Jemelle, Belgium).
Generation of RSV extracts
RSV A2 was added to HEp2 cells (IMDM with L-glutamin,
HEPES and 1% FSC) and incubated for six days. Cells were lysed
(0.5% NP-40) [26]) and used for ELISAs.
Also PEG-precipitated RSV lysate was prepared. Slowly ice
cold 50% PEG6000 in 150 mM NaCl, 1 mM EDTA and 6.1 g/L
Tris was added to RSV-infected Hep2 cells while stirring (end
concentration PEG was 10%). The mixture was stirred at 4uC for
three hours. The PEG-precipitated virus mixture was centrifuged
(30 min, 4000 rpm at 4uC). Supernatant was removed and the
pellet taken up in 10% sucrose and stored in N2.
Isolation and culture of human myeloid cells
Ethical approval of the use of blood samples was obtained from
the institutional review boards the ‘Medical Ethical Committee’ of
the UMC Utrecht, The Netherlands and Sanquin Blood Supply,
The Netherlands. Review and approval was obtained prior to the
experiments were conducted and are in accordance with the
declaration of Helsinki. Donors provided written informed consent
and the blood samples were used anonymously. Blood was
obtained at the UMC Utrecht (collected in heparin vacutainers
(BD Biosciences) or buffy coats (Sanquin blood supply, The
Netherlands) were diluted 1:1 in PBS. Diluted blood was layered
on top of a Histopaque-ficoll gradient and centrifuged for 25 min,
1500 rpm, slow acceleration and without brake. PBMCs and
PMNs were harvested and washed in RPMI. Red blood cells were
lysed with ammonium buffer (pH 7, UMC Utrecht pharmacy) for
10 minutes on ice.
Monocytes were purified using CD14 microbeads (Myltenyi
biotec, Bergisch Gladbach, Germany), according the manufactur-
ers prescriptions, with the following modifications: cells were
incubated in half the volume of MACS buffer and CD14 beads,
and incubated for 30 minutes on a roller at 4uC. Monocytes were
cultured in RPMI containing 10% FCS. For differentiation to
macrophages, monocytes were cultured overnight in the presence
of 10 ng/ml IFN-c (Peprotech, Rocky Hill, NJ, USA). Monocyte-
derived DCs (moDC) were differentiated for five days under the
influence of 50 ng/ml GM-CSF (Peprotech).
Binding of bIgG to cells expressing FccR
96 wells maxisorb plates (Nunc) were coated with Ig in 0.1 M
NaHPO4, pH 9 overnight (4uC). Cells were incubated with 5 mM
calcein AM (Invitrogen) in PBS (PMNs were labelled in HEPES
[27]) for 30 min at 37uC (PMNs for 20 min), washed with RPMI
containing 0.2% gelatin. 1.5*105 calcein-labelled cells were added,
centrifuged (500 rpm, 5 min) and allowed to attach for 45 min at
37uC (10 min for PMN) in RPMI containing 0.2% gelatin. Initial
fluorescence and fluorescence after several washing steps was
recorded (excitation 485 nm, emission 527 nm, ThermoFisher
Scientific Fluoroskan Ascent FL). For FccR-specific inhibition of
binding of calcein-labelled cells 2 or 5 mg/ml Fab fragments of
clone 3G8 (FccRIII) or IV.3 (FccRII) were used. Stable FccRI-
transfected IIA1.6 cells were previously shown to bind to human
IgG but not bIgG and were therefore not included in this study
[28].
Pathogen-specific Ig cell-binding assay
96 wells maxisorb plates were coated with PEG-precipitated
RSV at 4uC overnight. Plates were washed (PBS) and blocked with
1% gelatine/PBS (1 hour 37uC) and washing three times (PBS-
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tween). Bovine or human IgG (or buffer) was allowed to bind to
RSV for 3 hours at room temperature. Plates were washed 3 times
followed by washing once with RPMI containing 0.2% gelatine.
The assay was continued as described under ‘Binding of IgG to
human FcyR’.
FccR-mediated internalisation assay
8*105 CFU/ml FITC-labelled S. epidermidis was incubated
with 20 ml of varying concentrations of IVIg or bIgG overnight at
4uC. Twenty ml of pre-cooled cells (1.5*105) were added and
incubated with the bacteria on ice for 30 min. Plates were washed
and incubated at 37uC or 4uC (45 min. macrophages, 20 min
moDCs) in 150 ml RPMI. Cells were washed and stained with 1/
200 biotinylated anti FITC antibodies (Southern Biotec), followed
by washing and 1/100 streptavidin APC (eBiosciences). Cells were
washed and fixed with 1% PFA/PBS and analysed on FACS
Canto II. All washing steps were performed three times with ice-
cold FACS buffer and a cooled centrifuge at 1500 rpm for
5 minutes.
GFP-RSV internalisation assay
Renilla-GFP RSV (1*10‘5 plaque forming units (PFU)) was pre-
incubated for 1 hour at 37uC with 40 ml RPMI (10% FCS and 1%
pen/strep) in the presence or absence of antibodies and then
cooled for 15 min on ice. Pre-cooled PMN (1.5*10‘5 cells) and
40 ml RSV-Ig mixture was added and allowed to bind for 15 min
in 96-wells plates. Plates were washed and incubated for 15 min at
37uC in pre-warmed RPMI. After washing, cells were treated with
trypsin for 10 min on ice to remove extracellular RSV. Cells were
incubated twice (30 sec) with acid medium (RPMI pH 2.5, 0.1%
FCS) to remove FcR bound RSV-Ig, with a 1 min centrifugation
step (1500 rpm) in between and afterwards. Finally, cells were
washed and fixed with 1% PFA in PBS and GFP expression was
analysed by flow cytometry.
RSV neutralisation assay
HEp2 cells (5*10‘4 cells) cultured in IMDM (10% FCS, 1%
pen/strep) were seeded overnight in flat-bottom 96-wells plates.
Renilla-GFP RSV (1*10‘5 PFU) was pre-incubated for 1 hour at
37uC with 100 ml medium (1% FCS) in the presence or absence of
antibodies and then added to the cells. Cells were trypsinised after
18–24 hour incubation and GFP expression was analysed by flow
cytometry.
Results
Binding of bIgG to human respiratory tract pathogens
To study binding of purified human plasma IgG (IVIg) and
bovine colostrum IgG (bIgG) to human RSV (hRSV) lysate of
HEp2 cells (control) or RSV infected HEp2 cells was coated to an
ELISA plate. Dose-dependent binding of bIgG to RSV (.2 SD
above background) was observed at concentrations starting at
1.8 mg/ml (Figure 1A).
IVIg and bIgG also bound to flu and Hib antigens (Figure 1A).
Pathogen-specific bIgG could be detected at levels up to 11 mg/
ml. Compared to bIgG, less IVIg was required to detect the
pathogens. Binding of bIgG to rhinovirus was only detectable at
very high IgG levels (data not shown). hRSV, HIB and influvac-
specific IgG could also be detected in pooled bovine milk samples
(not shown).
To test the specificity of the bIgG-binding to human respiratory
pathogens, inhibition ELISAs were performed. These experiments
confirmed the specificity of the binding of bIgG to RSV, influenza
and Hib (Figure 1B). However, binding of bIgG to flu could also
be partly inhibited by Hib, suggesting the presence of cross
reactive epitopes.
Binding of bIgG to human FccRs
To study binding of bIgG to human FccRs, monocytes were
incubated overnight in the presence or absence of IFN-c to
enhance FccR expression, and exposed to plate-bound bIgG.
Human monocytes of 5 out of 5 donors bound to immobilised
bIgG, as well as to IVIg, which was increased by pre-incubating
the cells with IFN-c (Figure 2A). Binding of monocytes to bIgG
was dose-dependent and comparable or slightly lower compared
to human IVIg (Figure 2B).
Also binding of PMN to bIgG was evaluated. PMNs of 4/5
donors bound to IVIg as well as to bIgG (Figure 2C).
To identify which receptor was involved in binding of PMN to
bIgG, unstimulated PMN which lack FccRI [29], were incubated
with FccRII (Fab)- and FccRIII (F(ab)2)-specific blocking mAb
prior to addition of the cells to the Ig-coated plates (Figure 2C).
Pre-incubation with FccRII-blocking Fabs reduced binding of
PMN to bIgG of all three donors tested. Binding of PMN in both
the presence and absence of FccRII-specific Fabs was comparable
for IVIg and bIgG, although some donor-specific differences were
observed. Pre-incubation of PMN with FccRIII-specific Fabs
resulted in slightly decreased binding of IVIg, but not of bIgG.
Binding of macrophages and PMN to RSV-specific Ig
To study whether human phagocytes can bind to bIgG that has
captured RSV, an experiment was performed requiring bIgG to
simultaneously bind to RSV immobilised on a plate and human
macrophages (Figure 3A). Binding of cells to RSV-specific IVIg or
bIgG was dose-dependent and lost when IgG was (boiled prior to
addition to the plate). No binding was observed when plates were
coated with gelatin instead of RSV (data not shown). Bovine RSV-
specific IgG was also able to bind simultaneously to RSV and
PMN (Figure 3B).
Next, PMN were pre-incubated with anti FccRII and/or anti
FccRIII Fabs prior to addition to RSV-bound Ig. Pre-incubation
of PMN with anti FccRII, but not anti FccRIII Fabs, reduced
binding of PMN to RSV-specific IVIg and bIgG (Figure 3B). Pre-
incubation of Ig with RSV completely inhibited cell-binding,
confirming that cell-binding in this assay is indeed RSV-specific.
bIgG induces FccR-mediated phagocytosis
In addition to extracellular binding of pathogens, internalisation
is required for efficient clearance of pathogens and efficient
induction of memory T cells. FITC-labelled bacteria (S.
epidermidis) were used as model for bIgG-mediated internalisation
of pathogens by macrophages and moDCs. To discriminate
between extracellular bound bacteria and internalised bacteria,
APC-conjugated antibodies recognising FITC were used.
Medium, S. epidermidis left non-opsonised or opsonised with
different concentrations of IVIg or bIgG were added to
macrophages. Cells were allowed to bind to bacteria at 4uC,
washed and incubated at 37uC (allowing internalisation) or 4uC
(allowing binding, but not internalisation) for 45 minutes. Subse-
quently, cells were stained with APC anti FITC. Both IVIg and
bIgG enhanced the binding of bacteria to macrophages, indicated
by increased percentages of cells that are FITC positive
(Figures 4A and B). Also internalisation (FITC+APC2) of bacteria
was enhanced by IVIg and bIgG. The increased binding and
internalisation was dose-dependent, and only observed for cells
incubated at 37uC.
Similarly, bIgG enhanced internalisation of S. epidermidis by
moDCs of three other donors (Figure 4C). These data show that
HRSV-Specific IgG from Bovine Milk
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bIgG is able to enhance binding as well as internalisation of
pathogens by human immune cells.
Binding and internalisation of soluble hRSV by human
PMNs
PMN, like macrophages, play a crucial role in the elimination of
opsonised pathogens. To investigate whether pathogen-opsonisa-
tion by bIgG can enhance internalisation by human PMNs GFP-
labelled hRSV was opsonised with bIgG. In the absence of
antibodies little internalisation of hRSV by human PMN was
observed, measured as the percentage of GFP positive cells by flow
cytometry (Figure 5). By contrast, pre-incubation of hRSV with
both IVIg and bIgG resulted in a dose-dependent increase of
hRSV internalisation. While IVIg was more effective than bIgG at
the two highest concentrations tested, bIgG was particularly more
effective at lower concentrations.
Neutralisation of HEp2 infection by RSV
Pre-term birth children receive intravenous palivizumab to
prevent RSV infection [30]. The F-protein epitope recognised by
palivizumab seems to be conserved between human and bovine
RSV as palivizumab also recognises the F protein of bovine RSV
(data not shown). Therefore, like palivizumab, bIgG might be able
to prevent infection with hRSV. To this aim GFP-renilla-RSV was
pre-incubated with bIgG, IVIg or palivizumab and added to
HEp2 cells. After 18–24 hours incubation, cells were harvested
and analysed for GFP expression by flow cytometry. Both IVIg
and bIgG dose-dependently neutralised RSV, although 6.4 times
more bIgG compared to IVIg was needed to inhibit HEp2 cell
infection by RSV (IC50: 64 and 10 mg/ml, respectively)
(Figure 6B).
Discussion
Pathogen-specific immunoglobulins are supplied to newborns
through breastfeeding. These immunoglobulins help to protect the
neonate against infections by pathogenic bacteria and viruses.
Neonates, especially those born pre-maturely, are relatively
vulnerable to pathogenic infections in the respiratory tract [2].
We aimed to study whether intact bovine milk-derived immuno-
globulins can modulate immune responses to respiratory patho-
gens. The data presented here show that bIgG recognises several
pathogens that are known to cause infections in the respiratory
tract of infants. In addition, bIgG bound to human FccRII, and
enhance phagocytosis of pathogens by human myeloid immune
cells. Bovine IgG was shown to bind to human RSV, and could
even prevent infection of HEp2 cells by human RSV in vitro.
Cows are susceptible to pathogens like bovine RSV, and
transfer bovine RSV-specific antibodies into colostrum and
mature milk after delivery [31,32]. Those observations suggest
that cow’s indeed seem to develop neutralising antibodies against
bRSV, that cross-react with hRSV. It is relevant to note that even
though significant levels of bIgG specific for human respiratory
pathogens were detected, the cows were not immunised against
human pathogens. However, it is common practice to vaccinate
calves against bovine RSV around weaning when the maternal-
derived IgG levels are decreasing. Our data suggest that for RSV,
protecting the calf against bRSV through immunisation may give
rise to milk that has the potential to be protective against bovine as
well as human RSV.
bIgG was also able to neutralise infection of HEp2 cells with
hRSV. Compared to palivizumab, a humanized anti-RSV
therapeutic mAb, and IV-Ig, a significantly higher concentration
of bIgG was required for neutralisation of infection of HEp2 cells
by hRSV. Palivizumab is often given prophylactically and
therefore is present at the moment when hRSV is encountered
by the neonate. Direct neutralization of hRSV by orally deposited
bIgG on mucosal surfaces is possible, but not very likely. Activated
Figure 1. bIgG binds to human airway pathogens. A) RSV, influenza or Haemophilus influenzae type b was coated in ELISA plates and human
(IVIg) or bovine (bIg) IgG was added in different concentrations (x-axes in mg/ml). Mean OD or delta OD (RSV) values and S.E.M. are shown of triplicate
measurements. B) Inhibition of binding of IVIg (left) or bIg (right) to vaccines by pre-incubating the Ig-samples (167 mg/ml) with the antigen.
Horizontal text below graphs indicates vaccine used for coating, whereas diagonal text indicates the vaccine used for pre-incubation; ‘2’ indicates
pre-incubation with medium. Mean and S.E.M. of triplicate measurements are shown.
doi:10.1371/journal.pone.0112047.g001
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Figure 2. bIgG binds to human FccRII. A) IgG was immobilised on 96 wells ELISA plates. Monocytes were incubated overnight in the absence or
presence of 10 ng/ml IFN-c. B) Different concentrations of IgG were coated and IFN-c stimulated monocytes were added. C) Binding of PMNs to
10 mg/ml human (IVIg) and bovine IgG (bIg). PMNs were incubated for 10 minutes in the absence (–) or presence of 3 mg/ml Fabs recognizing FccRIII
(CD16) or FccRII (CD32). As negative control, plates were coated with gelatin (none) instead of Ig. Binding of bIgG by monocytes and PMNs was
observed for three different donors. For all panels binding of cells after five washes is shown and expressed as percentage of initial. Mean and S.E.M. is
shown of triplicate measurements.
doi:10.1371/journal.pone.0112047.g002
Figure 3. Bovine IgG simultaneously binds to human RSV and human FccRII. Plates were coated with PEG-precipitated RSV, grown in HEp2
cells. A) Varying concentrations of human (IVIg) or bovine (bIgG) Ig were added, followed by incubation with calcein-labelled macrophages. A
representative example of four donors tested is shown. No binding of cells was observed when Ig was inactivated prior to addition to the plate, or
when Ig was added to gelatine coated plates (data not shown). B) 1000 mg/ml IVIg or bIgG was added to RSV-coated plates. PMNs were pre-
incubated with medium, and/or anti FccRII (CD32) or FccRIII (CD16) Fabs. Independent experiments were performed with three donors. Graphs show
mean and S.E.M. of triplicate measurements.
doi:10.1371/journal.pone.0112047.g003
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T and B cells recirculate throughout the body and home to
different tissues. Tissue specific homing explains why oral
administration of antigen-specific IgG leads to increased presence
of memory T and B cells in other organs like the lungs and the
breasts [33,34,35,36,37]. Likewise, passive oral vaccination has
been shown to induce active immune responses in the gastro-
intestinal (GI) tract, but also in the upper airways and in breast
tissue [38]. Therefore, bIgG consumption may induce adaptive
immunity against respiratory pathogens in a similar manner.
Dietary bIgG encounters swallowed respiratory pathogens in the
GI tract or in the tonsillar crypts in Waldeyer’s ring, forming
immune-complexes that efficiently bind to DCs in the tissue
[39,40].
As bIgG can bind to RSV, this may lead to viral uptake through
FccR-mediated phagocytosis and, therefore, may facilitate an
enhanced T-cell response through binding to FccRII, as reported
by Gosselin for human IgG [41]. The interaction of bIgG with
hFccRII and internalisation of bIgG immune-complexes has been
observed for multiple donors, indicating it is a robust phenomenon
(Table S1).
As shown in Figure 3, bIgG could bind simultaneously to hRSV
and FccRII on human innate immune cells, and moDCs could
internalise bIgG-coated hRSV, which is needed for antigen
presentation. This confirms earlier findings that demonstrated
binding of bIgG to human FccRII expressed on myeloid cells [42].
Cross-linking of FccRII by DCs causes NFkß activation and
Figure 4. bIg-mediated binding and phagocytosis of S.
epidermidis by IFN-c-stimulated monocytes and GM-CSF-differ-
entiated moDCs. FITC-labelled bacteria were opsonised or not with
human (IVIg) or bovine (bIgG) IgG. Subsequently cells were allowed to
bind to opsonised bacteria and incubated at 4uC (negative control) or
37uC degrees and stained with APC-conjugated antibodies recognizing
FITC. Extracellular bacteria were defined as FITC+APC+ and intracellular
bacteria as FITC+APC2. Extracellular bacteria can be observed at both
4uC and 37uC incubated cells, whereas intracellular bacteria are only
present in cells incubated at 37uC. A) Example of FACS dot plot and
gating strategy. B and C) Percentage of IFN-c conditioned monocytes
(B) and moDCs (C) with extracellular (left) and intracellular (right)
bacteria of IVIg (top) and bIgG (bottom) incubated at 4uC or 37uC
(indicated at x-axes). Black bars indicate medium (–) or bacteria alone
without Ig (0). X-axes show mg/ml Ig used for opsonisation of bacteria.
Mean and S.E.M. of triplicate measurements are shown of one out of
three donors tested.
doi:10.1371/journal.pone.0112047.g004
Figure 5. Bovine Ig enhances internalisation of hRSV by hPMN.
GFP-renilla expressing RSV was pre-incubated with medium in the
presence or absence of IVIg or bIgG and allowed to bind to PMN at 4uC.
Subsequently, cells were incubated at 37uC and thereafter treated with
trypsin and acid to remove extracellular RSV. Cells were then washed
and analysed by flow cytometry for the percentage of GFP+ cells. GFP+
cells were tested in the absence of RSV (–), in the presence of RSV but
absence of Ig (0) and in the presence of IVIg or bIgG (mg/ml). Mean and
S.E.M. of triplicate measurements of one out of five donors tested are
shown.
doi:10.1371/journal.pone.0112047.g005
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maturation of DCs [39]. FccRII-mediated antigen uptake and
presentation, as well as DC maturation is crucial for activation and
differentiation of T cells. As a result bIgG may facilitate adaptive T
cell responses. This can thus result in long-lasting protection
against airway pathogens via the T-cell dependent induction of
pathogen-specific (IgA) antibodies in the upper airways.
Our current findings are based on various in vitro assays and
require in vivo studies to show formally demonstrate that like Ig
from breast milk, bIgG can assist the development of immune
memory responses. Another aspect that needs further study is how
effective bIgG is in inducing protective immunity in immunocom-
promised individuals, like children suffering from recurrent asthma
caused by viral infections, and in newborns in whom the immune
system has not yet matured. Therefore, inclusion of intact bIgG in
infant nutrition may contribute to the induction of adaptive
immunity against airway infections. Interestingly, several epide-
miological studies have linked the consumption of milk to a
reduced incidence of asthma [43,44,45,46]. This effect was later
shown to be associated with the consumption of raw milk, and the
detectability of intact milk proteins [47]. As RSV infections may
predispose infants to develop asthma at a later age [6,7,8], we
would like to speculate that there is a possibility that the effect we
describe here for RSV-specific bovine antibodies may contribute
to the effect of raw milk consumption on asthma development.
Although nutritional intervention studies are needed to formally
demonstrate if dietary bIgG can contribute to protection against
respiratory pathogens, and possibly also against the development
of asthma, the in vitro data reported here support this concept.
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